Ruxolitinib cream (Opzelura, Incyte) demonstrated sustained disease control over 24 weeks in adults with moderate atopic dermatitis (AD) who had an inadequate response, intolerance, or contraindication to topical corticosteroids (TCSs), and topical calcineurin inhibitors (TCIs), according to data from the Phase 3 TRuE-AD4 study.
These data were presented at the 2026 European Academy of Dermatology and Venereology (EADV) Symposium in Athens, Greece.
As previously reported, the TRuE-AD4 study met both of its co-primary endpoints at Week 8, with a statistically significantly higher proportion of patients on ruxolitinib cream vs. vehicle cream achieving ≥75% improvement in Eczema Area and Severity Index score (EASI-75) from baseline) and, separately, Investigator’s Global Assessment Treatment Success (IGA-TS), defined as an Investigator’s Global Assessment (IGA) score of 0 [Clear] or 1 [Almost Clear] with at least a two-point improvement from baseline).
Patients who achieved an EASI-50 response at Week 8 continued double-blind treatment, as needed, through Week 24. Most patients (84.3%) in the ruxolitinib cream treatment group completed treatment through Week 24. Among those patients, 84.3% achieved EASI-75 and 70.6% achieved IGA-TS at Week 24, similar to the frequencies at Week 8 (83.5% and 74.4%, respectively). Mean affected body surface area (BSA) remained low (2.5% at Weeks 8 and 24) and itch relief ≥4-point improvement in Itch Numeric Rating Scale (NRS4) remained high (74.3% at Week 8 and 64.7% at Week 24) with ruxolitinib cream treatment.
As-needed treatment with ruxolitinib cream was well-tolerated, with few application-site reactions (1.7%) and no new safety signals up to 24 weeks. The most common treatment-emergent adverse events were upper respiratory tract infection (10.6%) and nasopharyngitis (6.3%).
Data support Type-II variation application submitted for ruxolitinib cream 1.5% for the treatment of adults with moderate AD in the European Union (EU). Feedback is expected in the first half of 2026.